News &

Press

venBio news

“venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies.”

“venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences.”

“venBio Closes $394 Million Life Sciences Venture Capital Fund.”

Portfolio news

Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE

Nov 13, 2020

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors

Nov 9, 2020

Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients

Nov 9, 2020

Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy

Oct 14, 2020

RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics

Oct 14, 2020

Metacrine Announces Pricing of Initial Public Offering

Sep 15, 2020

Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis

Sep 14, 2020

San Francisco office

1700 Owens Street, Suite 595
San Francisco, CA 94158

Seattle office

1200 Westlake Ave N, Suite 900
Seattle, WA 98109

© 2024 venBio. All Rights Reserved.